7 August 2018 - List prices of prescription drugs continue to rise, albeit at a much slower pace than several years ago. 

Most of the increase in drug prices and patient cost-sharing (often in the form of co-insurance or a percentage off of list prices) is attributed to specialty pharmaceuticals.

Rebates, as inferred approximately from gross to net difference in sales figures, are also increasing. Drug companies say that the rebate growth rate has outstripped list prices. Pharmacy benefit managers assert that through rebates they’re stemming increases in premiums. But, what do end-users see? The insured are faced with ever-rising premiums and cost-sharing. And, without negotiating clout the growing ranks of uninsured pay the full retail price of prescription drugs.

Read Forbes article